Page last updated: 2024-09-04

torcetrapib and pyrroles

torcetrapib has been researched along with pyrroles in 41 studies

Compound Research Comparison

Studies (torcetrapib)	Trials (torcetrapib)	Recent Studies (post-2010) (torcetrapib)	Studies (pyrroles)	Trials (pyrroles)	Recent Studies (post-2010) (pyrroles)
273	28	83	26,129	2,815	12,100

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (82.93)	29.6817
2010's	7 (17.07)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brewer, HB	1
Bloedon, LT; Brousseau, ME; Clark, RW; Digenio, AG; Mancuso, JP; Rader, DJ; Schaefer, EJ; Wolfe, ML	1
Angelin, B; Asztalos, BF; Björkhem, I; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Rudling, M; Schaefer, EJ; Welty, FK; Wolfe, ML	1
Avorn, J	1
Bays, H; Davidson, M; McKenney, J	1
Burnett, JR	1
Shear, CL	1
Green, AM	1
Hirsch, RL	1
Zareba, G	1
Barrett, PH; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Dolnikowski, GG; Faruqi, A; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Schaefer, EJ; Welty, FK; Wolfe, ML	1
Einecke, D	1
Davidson, MH; McKenney, JM; Revkin, JH; Shear, CL	1
Wadman, M	1
Tall, AR; Wang, N; Yvan-Charvet, L	1
Honey, K	1
Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM	1
Tall, AR	1
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI	1
Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI	1
Mazzone, T	1
Bots, ML; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; Tegeler, CH; Vicari, RM; Visseren, FL	1
Chapman, MJ; Duchene, E; Guerin, M; Julia, Z; Le Goff, W; Nguyen, T; Shear, CL; Thuren, T	1
Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD	1
Barrett, PH; Brousseau, ME; Cohn, JS; Diffenderfer, MR; Digenio, AG; Dolnikowski, GG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Schaefer, EJ; Schaefer, PM; Welty, FK; Wilson, A; Wolfe, ML	1
Levy, Y	1
Doggrell, SA	1
Cohn, LJ	1
de Haan, W; de Vries-van der Weij, J; Gautier, T; Havekes, LM; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; van der Hoorn, JW; Westerterp, M	1
Brennan, DM; Nicholls, SJ; Nissen, SE; Tardif, JC; Tuzcu, EM	1
Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL	1
Catalano, G; Chapman, MJ; Fournier, N; Frisdal, E; Guerin, M; Julia, Z; Le Goff, W; Vedie, B	1
Asztalos, BF; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Schaefer, EJ; Wolfe, ML	1
Funder, JW	1
Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL	1
Mombelli, G; Sirtori, CR	1
Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD	1
Schaefer, JR	1
Bellanger, N; Chapman, MJ; Duchene, E; El Khoury, P; Fournier, N; Guerin, M; Julia, Z; Le Goff, W; Villard, EF	1
Barter, PJ; Beltangady, MS; Boekholdt, SM; DeMicco, DA; Duggan, WT; Kastelein, JJ; Ports, WC; Rye, KA; Shear, CL	1

Reviews

3 review(s) available for torcetrapib and pyrroles

Article	Year
Torcetrapib/atorvastatin combination therapy. Expert review of cardiovascular therapy, 2005, Volume: 3, Issue:5 Topics: Animals; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines	2005
Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:9 Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone	2010
[HDL level or HDL function as the primary target in preventive cardiology]. Herz, 2012, Volume: 37, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation	2012

Trials

18 trial(s) available for torcetrapib and pyrroles

Article	Year
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Single-Blind Method; Triglycerides	2004
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:5 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Bile Acids and Salts; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Feces; Glycoproteins; Heptanoic Acids; Humans; Pyrroles; Quinolines; Sterols	2005
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:6 Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Drug Synergism; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipids; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Pyrroles; Quinolines; Single-Blind Method	2006
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. Journal of the American College of Cardiology, 2006, Nov-07, Volume: 48, Issue:9 Topics: Adult; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Quinolines	2006
Drug designed to raise HDL levels falls down. The Journal of clinical investigation, 2007, Volume: 117, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Industry; Heart Diseases; Heptanoic Acids; Humans; Lipoproteins, HDL; Pyrroles; Quinolines	2007
Effect of torcetrapib on the progression of coronary atherosclerosis. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional	2007
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2007
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography	2007
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582 Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Quinolines; Tunica Intima	2007
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:1 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Chylomicrons; Dietary Fats; Dietary Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Quinolines	2008
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines	2007
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. Journal of lipid research, 2008, Volume: 49, Issue:3 Topics: Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Kinetics; Lipoproteins, VLDL; Male; Pyrroles; Quinolines; Single-Blind Method	2008
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi Circulation, 2008, Dec-09, Volume: 118, Issue:24 Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Potassium; Pyrroles; Quinolines; Sodium; Ultrasonography	2008
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation, 2008, Dec-09, Volume: 118, Issue:24 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol Ester Transfer Proteins; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mineralocorticoids; Pyrroles; Quinolines	2008
Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:2 Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL2; Lipoproteins, HDL3; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrroles; Quinolines; Scavenger Receptors, Class B; Time Factors; Treatment Outcome	2009
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. Journal of lipid research, 2009, Volume: 50, Issue:7 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Placebos; Pyrroles; Quinolines	2009
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Annals of medicine, 2010, Volume: 42, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography	2010
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2011

Other Studies

20 other study(ies) available for torcetrapib and pyrroles

Article	Year
Increasing HDL Cholesterol Levels. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Transport; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Triglycerides	2004
Torcetrapib and atorvastatin--should marketing drive the research agenda? The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25 Topics: Anticholesteremic Agents; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Approval; Drug Combinations; Drug Industry; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Marketing; Molecular Structure; Pyrroles; Quinolines; Research Design; United States; United States Food and Drug Administration	2005
Torcetrapib + atorvastatin (Pfizer). Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:9 Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines	2005
Torcetrapib and atorvastatin. The New England journal of medicine, 2005, Oct-06, Volume: 353, Issue:14 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Combinations; Drug Industry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines	2005
Torcetrapib and atorvastatin. The New England journal of medicine, 2005, Oct-06, Volume: 353, Issue:14 Topics: Atorvastatin; Drug Combinations; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Legislation, Drug; Patents as Topic; Pyrroles; Quinolines; United States	2005
Torcetrapib and atorvastatin. The New England journal of medicine, 2005, Oct-06, Volume: 353, Issue:14 Topics: Atorvastatin; Drug Costs; Drug Industry; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Ritonavir	2005
Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:2 Topics: Animals; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Quinolines	2006
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2006
Cholesterol: the good, the bad, and the stopped trials. Lancet (London, England), 2006, Dec-09, Volume: 368, Issue:9552 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Failure	2006
When the party's over. Nature, 2007, Jan-04, Volume: 445, Issue:7123 Topics: Atorvastatin; Clinical Trials as Topic; Drug Industry; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure	2007
The failure of torcetrapib: was it the molecule or the mechanism? Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:2 Topics: Angina Pectoris; Animals; Anticholesteremic Agents; Atorvastatin; Cardiac Output, Low; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Mice; Myocardial Revascularization; Pyrroles; Quinolines; Rabbits; Treatment Failure	2007
CETP inhibitors to increase HDL cholesterol levels. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines	2007
HDL cholesterol and atherosclerosis. Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Pyrroles; Quinolines; Tunica Intima	2007
High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovascular research, 2008, Mar-01, Volume: 77, Issue:4 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Quinolines; Treatment Outcome	2008
The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Pyrroles; Quinolines; Research Design	2008
Torcetrapib and coronary events. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure	2008
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation, 2008, May-13, Volume: 117, Issue:19 Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Synergism; Heptanoic Acids; Inflammation; Mice; Mice, Inbred Strains; Pyrroles; Quinolines	2008
Cholesteryl ester transfer protein antagonism by drugs--a poor choice. Clinical chemistry, 2010, Volume: 56, Issue:10 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk	2010
Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis, 2012, Volume: 221, Issue:1 Topics: Adult; Animals; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; CD36 Antigens; CHO Cells; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cricetinae; Cricetulus; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL2; Liver; Macrophages; Male; Mice; Middle Aged; Paris; Particle Size; Postprandial Period; Pyrroles; Quinolines; Time Factors; Transfection; Treatment Outcome	2012
Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines	2012